Table 4.
Pharmacodynamics summary for 3–12 mg BLZ-100 dose cohorts.
| Subject | Lesion No. | Dose (mg) | Pathology of formalin-fixed samples | BLZ-100 uptake in lesion | Kinetics – Contrast observed: |
|
|---|---|---|---|---|---|---|
| Day of dosing | Day after dosing | |||||
| R201 | 1 | 3 | BCC | Yes | Yes | Yes |
| R202 | 1 | 3 | Scar; no residual viable lesion identified | No | – | – |
| R203 | 1 | 3 | BCC | Yes | Yes | Yes |
| R301 | 1 | 6 | BCC | Yes | Yes | No |
| 2 | Minor scar + upper dermal lymphocytic infiltration | Yes | Yes | No | ||
| R302 | 1 | 6 | BCC | No | – | – |
| R303d | 1 | 6 | BCC | Yes | Yes | Yes |
| 2 | BCC | Yes | Yes | No | ||
| R304 | 1 | 6 | Melanoma in situ | Yes | Yes | Yes |
| R305 | 1 | 6 | Melanoma in situ | Yes | No | Yes |
| R306 | 1 | 6 | Melanoma in situ | Yes | Yes | No |
| R401 | 1 | 12 | Multifocal lichenoid solar keratosis | No | – | – |
| R402 | 1 | 12 | No dysplasia, tumor, or other specific lesion identified | Yes | Yes | Yes |
| R403 | 1 | 12 | Dermal scar; mild junctional melanocytic atypia | Yes | Yes | Yes |
| R404 | 1 | 12 | No residual melanoma identified | No | – | – |
| R405 | 1 | 12 | No residual melanoma; incidental solar keratosis; large cell acanthoma present | Yes | Yes | Yes |
| R406 | 1 | 12 | Biopsy site and residual melanoma in situ (level 1) | Yes | Yes | Yes |